Amalgamated Financial’s Phathom Pharmaceuticals PHAT Stock Holding History

Amalgamated Financial’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$45K	Buy	+3,309	New	+$53.5K	﹤0.01%	2483

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Amalgamated Financial's PHAT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Phathom Pharmaceuticals (PHAT) in Q1 2022: 3,309 shares worth $45K. The stake represents ﹤0.01% of the portfolio and ranks #2483 among its holdings.

82 funds tracked by Wall St. Rank hold PHAT as of Q1 2022.

Amalgamated Financial held 3,309 shares of Phathom Pharmaceuticals worth $45K as of Q1 2022.
Phathom Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Phathom Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2483 holding.
82 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.